Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • jpjp
    Junior Member
    • Oct 2010
    • 7

    #1

    Mapping vs denovo assembly for non-SNP genomic variations

    Hi Guys,

    even though I have been working with NGS for a while it is not clear to me why mapping onto a reference genome is preferred to denovo assembly to decipher genomic variations like CNV, inversions, translocations etc.

    I guess one issue is the difficulty in confidently assembling the entire sequence from short reads. But given that most of the new data is paired end and the read lengths are increasing steadily, what other problems do you see with denovo assembly? If this issue is resolved, then would denovo assembly identify the genomic variations more accurately and confidently?

    Thoughts and insights are welcome, especially in the light of BGI's push in this direction.

    Discover the latest news in bioinformatics, biomedical research, and drug discovery. Bio-IT World provides topical news coverage and analysis of cutting-edge biotechnologies to deliver individualized medicine.
  • jpjp
    Junior Member
    • Oct 2010
    • 7

    #2
    Just bouncing it.

    Nobody has an opinion on it??

    Comment

    • Shlomo Blum
      Member
      • Nov 2012
      • 10

      #3
      Nothing, eh?

      I'm working with bacterial genomes, and although I have plenty of refs out there (E. coli...), I still wonder what's best, de novo or mapping, since we aim to search for novel genes.

      Mapping to K-12 is giving us about 20% of unmapped reads (the novel genes?). Not bad. But still, would de novo give us more?

      SB

      Comment

      • krobison
        Senior Member
        • Nov 2007
        • 734

        #4
        Mapping is much faster & requires a much smaller compute power. You also have the annotations already mapped to the reference.

        How close is your organism to the reference genome? At a minimum, I would assemble the unmapped reads to see what falls out.

        Even with highly variable genomes, you can expect major failures from mapping only. As a trivial example, imagine mapping an F+ lambda+ E.coli K12 strain onto MG1655 -- you'd have a lot of interesting biology falling out as unmapped reads.

        Comment

        • Shlomo Blum
          Member
          • Nov 2012
          • 10

          #5
          They are the same species, but not the same phylogeny. Anyway, even if mapping to a reference, the idea is to assemble de novo whatever remains unmapped.

          The point is, how much a difference does it make to assemble either way? I was told that mapping improves coverage depth, but you may lose information. I just don't get if you lose information because of unmapped reads are "lost" or because mapped reads would actually be assembled differently in a de novo context.

          Also, going for a reference mapping option, how should I know ("bioinformatically", as much as possible) where in the genome (chromosome X plasmid) fall the de-novo-assembled-unmapped reads?

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            10-14-2026, 09:55 AM
          • SEQadmin2
            New Genomics Technologies Take Aim at Long-Standing Limits
            by SEQadmin2


            Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

            We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
            ...
            09-28-2026, 10:25 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 10-22-2026, 11:13 AM
          0 responses
          35 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 10:48 AM
          0 responses
          25 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-15-2026, 10:52 AM
          0 responses
          41 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-14-2026, 05:39 AM
          0 responses
          45 views
          0 reactions
          Last Post SEQadmin2  
          Working...